Literature DB >> 19116178

Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome.

Spiros Dendrinos1, Evangelos Sakkas, Evangelos Makrakis.   

Abstract

OBJECTIVE: To compare low-molecular-weight (LMW) heparin plus low-dose aspirin with intravenous immunoglobulin (IVIG) in the treatment of antiphospholipid antibody syndrome in women with recurrent spontaneous abortions before 10 weeks of gestation.
METHOD: This prospective, multicenter trial conducted between 2002 and 2006 included 85 patients aged 18-39 years. The women were allocated randomly to receive LMW heparin plus low-dose aspirin, or IVIG. Data were compared using the t test and Fisher exact test.
RESULTS: The women treated with LMW heparin plus low-dose aspirin had a higher rate of live births than those treated with IVIG (P=0.003). Of those who completed the study, 29/40 (72.5%) and 15/38 (39.5%), respectively, had live births. Intent-to-treat analysis revealed a significant difference between the 2 groups (OR 1.802; 95%CI, 1.14-2.84; P=0.007).
CONCLUSIONS: LMW heparin plus low-dose aspirin resulted in a higher live birth rate than IVIG in the treatment of antiphospholipid antibody syndrome in women with recurrent abortion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116178     DOI: 10.1016/j.ijgo.2008.11.010

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  17 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 2.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 3.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

4.  When conventional treatment fails: the role of intravenous immunoglobulin in recurrent pregnancy loss secondary to antiphospholipid syndrome.

Authors:  Jacklyn Chay; Karin Lust; Paul Kubler; Leonie Callaway
Journal:  Obstet Med       Date:  2013-05-03

Review 5.  Management of pregnancy in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 6.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 7.  Anticoagulation during pregnancy in patients with a prosthetic heart valve.

Authors:  Jose M Castellano; Rajeev L Narayan; Prashant Vaishnava; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2012-05-15       Impact factor: 32.419

8.  The role of aspirin in women's health.

Authors:  Freek Wa Verheugt; Antoinette C Bolte
Journal:  Int J Womens Health       Date:  2011-06-30

9.  Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis.

Authors:  Silvia D'Ippolito; Riccardo Marana; Fiorella Di Nicuolo; Roberta Castellani; Manuela Veglia; John Stinson; Giovanni Scambia; Nicoletta Di Simone
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 10.  Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.

Authors:  Malgorzata M Bala; Elżbieta Paszek; Wiktoria Lesniak; Dorota Wloch-Kopec; Katarzyna Jasinska; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.